Annex Advisory Services LLC Boosts Stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Annex Advisory Services LLC grew its stake in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 5.9% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 31,677 shares of the medical instruments supplier’s stock after buying an additional 1,769 shares during the period. Annex Advisory Services LLC’s holdings in LeMaitre Vascular were worth $2,919,000 at the end of the most recent reporting period.

Other institutional investors also recently made changes to their positions in the company. Glenmede Trust Co. NA increased its position in LeMaitre Vascular by 1.3% during the 3rd quarter. Glenmede Trust Co. NA now owns 10,512 shares of the medical instruments supplier’s stock worth $976,000 after purchasing an additional 136 shares in the last quarter. Summit Global Investments raised its position in shares of LeMaitre Vascular by 2.4% in the third quarter. Summit Global Investments now owns 6,192 shares of the medical instruments supplier’s stock valued at $575,000 after buying an additional 146 shares during the last quarter. NBC Securities Inc. lifted its stake in shares of LeMaitre Vascular by 73.2% during the third quarter. NBC Securities Inc. now owns 433 shares of the medical instruments supplier’s stock valued at $40,000 after buying an additional 183 shares during the period. GAMMA Investing LLC boosted its holdings in shares of LeMaitre Vascular by 34.3% during the third quarter. GAMMA Investing LLC now owns 736 shares of the medical instruments supplier’s stock worth $68,000 after purchasing an additional 188 shares during the last quarter. Finally, MML Investors Services LLC increased its stake in LeMaitre Vascular by 2.8% in the third quarter. MML Investors Services LLC now owns 7,107 shares of the medical instruments supplier’s stock valued at $660,000 after purchasing an additional 191 shares during the last quarter. 84.64% of the stock is owned by institutional investors and hedge funds.

LeMaitre Vascular Trading Up 0.8 %

LeMaitre Vascular stock opened at $99.06 on Monday. The stock has a market cap of $2.23 billion, a P/E ratio of 54.13, a price-to-earnings-growth ratio of 2.07 and a beta of 0.96. The stock has a 50 day moving average of $98.48 and a 200-day moving average of $91.95. LeMaitre Vascular, Inc. has a 52 week low of $56.04 and a 52 week high of $109.58.

LeMaitre Vascular (NASDAQ:LMAT) last issued its earnings results on Thursday, October 31st. The medical instruments supplier reported $0.49 EPS for the quarter, topping the consensus estimate of $0.44 by $0.05. The company had revenue of $54.82 million during the quarter, compared to analyst estimates of $53.50 million. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. The business’s revenue was up 15.6% on a year-over-year basis. During the same quarter last year, the firm earned $0.33 EPS. As a group, equities analysts predict that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current fiscal year.

LeMaitre Vascular Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, December 5th. Investors of record on Thursday, November 21st were paid a dividend of $0.16 per share. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.65%. The ex-dividend date was Thursday, November 21st. LeMaitre Vascular’s dividend payout ratio is currently 34.97%.

Analyst Ratings Changes

A number of research analysts have recently commented on the stock. Oppenheimer reaffirmed an “outperform” rating and set a $93.00 price objective (up previously from $90.00) on shares of LeMaitre Vascular in a research note on Friday, November 1st. Barrington Research upped their price objective on LeMaitre Vascular from $92.00 to $93.00 and gave the stock an “outperform” rating in a report on Friday, November 1st. StockNews.com lowered LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Friday, December 13th. Finally, Cantor Fitzgerald initiated coverage on LeMaitre Vascular in a research note on Tuesday, October 15th. They issued a “neutral” rating and a $96.00 price objective on the stock. Three research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $94.57.

Insider Activity at LeMaitre Vascular

In related news, Director Bridget A. Ross sold 3,750 shares of the firm’s stock in a transaction dated Friday, November 15th. The stock was sold at an average price of $101.47, for a total transaction of $380,512.50. Following the completion of the transaction, the director now owns 2,278 shares of the company’s stock, valued at $231,148.66. This trade represents a 62.21 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 10.79% of the stock is currently owned by insiders.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.